AYLA Ayala Pharmaceuticals Inc.

Biotech Analyst Ratings

Latest News

1. 16 May 2022 Ayala Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

   REHOVOT, Israel and WILMINGTON, Del., May 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced first-quarter 2022 financial results and provided a corporate update.
   

   "We continued to execute on advancing our clinical programs during the first quarter of 2022," said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala. "Our highest immediate priority is completing Part A of the RINGSIDE study evaluating AL102 in desmoid tumors and we are on target to announce initial interim data around mid-year…

   View Full Article
2. 27 April 2022 Ayala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

   REHOVOT, Israel and WILMINGTON, Del., April 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present a poster featuring data on AL101 in adenoid cystic carcinoma (ACC) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place June 3-7, 2022 in Chicago, Illinois.

   Details of the poster presentation are as follows:
   Abstract Title:	Results of ACCURACY: A phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic

   …

   View Full Article
3. 28 March 2022 Ayala Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update

   REHOVOT, Israel and WILMINGTON, Del., March 28, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Ayala or the Company) (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers today announced full-year 2021 financial results and provided a corporate update.
   

   "2022 is off to a very promising start for Ayala, following a number of important accomplishments across our pipeline of innovative gamma-secretase inhibitors in 2021," said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala. "We are pleased with the progress of our AL102 program in desmoid tumors, having recently completed enrollment in Part A of the open label…

   View Full Article
4. 09 March 2022 Ayala Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference

   REHOVOT, Israel and WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced that it will present at the 32^nd Annual Oppenheimer Healthcare Conference, taking place on March 15-17, 2022. The company will also participate in one-on-one investor meetings at the conference.
   

   Details on the presentation can be found below.

   32nd Annual Oppenheimer Healthcare Conference
   Format:	Virtual Presentation
   Date:	Tuesday, March 15, 2022
   Time:	10:40 AM – 11:10 AM EDT

   A webcast…

   View Full Article
5. 08 March 2022 Ayala Pharmaceuticals, MD Anderson Cancer Center and the Adenoid Cystic Carcinoma Research Foundation Announce Initiation of Enrollment in Window of Opportunity Study of AL101 in Adenoid Cystic Carcinoma

   REHOVOT, Israel and WILMINGTON, Del., March 08, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), together with M.D. Anderson Cancer Center and the Adenoid Cystic Carcinoma (ACC) Research Foundation are pleased to announce that the first five patients have been enrolled in a "Window of Opportunity" study for individuals with an aggressive, Notch-activated form of Adenoid Cystic Carcinoma. Under the leadership of Dr. Renata Ferrarotto at M.D. Anderson, this study is focused on determining the effects of AL101, a gamma-secretase inhibitor being developed by Ayala for the treatment of ACC and other cancers, on the biology of ACC tumors. 
   

   In this study, participants will have a biopsy to confirm the diagnosis of ACC with…

   View Full Article